U.S. Stock Market Update: Twist Bioscience plunges on October 16 due to high valuation, profit-taking, and ongoing losses.
Bitget异动解读2026/10/16 14:05Analysis of Twist Bioscience's Sharp Decline on October 16
Keywords: High valuation, profit-taking, continued losses
1. As of October 16, TWST had risen 324.65% year-to-date, but fell 15.70% over the past five trading days; the sharp pullback followed a substantial cumulative gain and was accompanied by pressures from profit-taking and valuation digestion.
2. On August 3, the company disclosed a quarterly loss of $0.56 per share as of June 30; continued losses combined with a significant share price increase have made its valuation more sensitive to growth realization expectations.
(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
French bond market under pressure, economists warn of risk transmission
Refining profit margins soar, ExxonMobil (XOM.US) Q3 downstream business profit set to reach historic high
ExxonMobil stated that the rise in Q3 refining margins is expected to increase profits by about $4.5 billion, although part of the growth will be offset by falling oil prices and the timing effect of derivatives losses.


The Sri Lanka Renminbi Clearing Bank officially launched operations.
